Drug firm Ind-Swift Laboratories is targeting to garner revenues of Rs 1,500 crore by 2015. For achieving the same, the company will continue to focus on its active pharmaceuticals Ingredients (API) business in European Union, Japan, Australia and US which will be the main drivers of growth for future. At present, the company’s revenues stand at over Rs 1,000 crore.
Ind-Swift Laboratories is a part of the Ind-swift Group and is based at Chandigarh, India. The company is engaged in manufacturing of Active Pharmaceutical Ingredients (API). The company’s business model is focused on domestic market and high-value mature regulated markets along with considerable focus on the emerging markets as well.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: